Expert Consensus on the Diagnosis and Treatment of Solid Tumors with BRAF Mutations
Wenxian Wang,Bin Lian,Chunwei Xu,Qian Wang,Ziming Li,Nan Zheng,Aijun Liu,Jinpu Yu,Wenzhao Zhong,Zhijie Wang,Yongchang Zhang,Jingjing Liu,Shirong Zhang,Xiuyu Cai,Anwen Liu,Wen Li,Lili Mao,Ping Zhan,Hongbing Liu,Tangfeng Lv,Liyun Miao,Lingfeng Min,Yu Chen,Jingping Yuan,Feng Wang,Zhansheng Jiang,Gen Lin,Long Huang,Xingxiang Pu,Rongbo Lin,Weifeng Liu,Chuangzhou Rao,Dongqing Lv,Zongyang Yu,Xiaoyan Li,Chuanhao Tang,Chengzhi Zhou,Junping Zhang,Junli Xue,Hui Guo,Qian Chu,Rui Meng,Xuewen Liu,Jingxun Wu,Rui Zhang,Jin Zhou,Zhengfei Zhu,Yongheng Li,Hong Qiu,Fan Xia,Yuanyuan Lu,Xiaofeng Chen,Jian Feng,Rui Ge,Enyong Dai,Yu Han,Weiwei Pan,Fei Pang,Xin Huang,Meizhen Hu,Qing Hao,Kai Wang,Fan Wu,Binbin Song,Bingwei Xu,Liping Wang,Youcai Zhu,Li Lin,Yanru Xie,Xinqing Lin,Jing Cai,Ling Xu,Jisheng Li,Xiaodong Jiao,Kainan Li,Jia Wei,Huijing Feng,Lin Wang,Yingying Du,Wang Yao,Xuefei Shi,Xiaomin Niu,Dongmei Yuan,Yanwen Yao,Jianhui Huang,Yue Feng,Yinbin Zhang,Pingli Sun,Hong Wang,Mingxiang Ye,Dong Wang,Zhaofeng Wang,Yue Hao,Zhen Wang,Bin Wan,Donglai Lv,Shengjie Yang,Jin Kang,Jiatao Zhang,Chao Zhang,Wenfeng Li,Jianfei Fu,Lizhi Wu,Shijie Lan,Juanjuan Ou,Lin Shi,Zhanqiang Zhai,Yina Wang,Bihui Li,Zhang,Ke Wang,Xuelei Ma,Zhongwu Li,Zhefeng Liu,Nong Yang,Lin Wu,Huijuan Wang,Gu Jin,Guansong Wang,Jiandong Wang,Hubing Shi,Meiyu Fang,Yong Fang,Yuan Li,Xiaojia Wang,Jing Chen,Yiping Zhang,Xixu Zhu,Yi Shen,Shenglin Ma,Biyun Wang,Yong Song,Zhengbo Song,Wenfeng Fang,Yuanzhi Lu,Lu Si
DOI: https://doi.org/10.1016/j.xinn.2024.100661
2024-01-01
Abstract:The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth, differentiation, and survival. When the BRAF gene mutates, it can lead to abnormal activation of the signaling pathway, which promotes cell proliferation, inhibits cell apoptosis, and ultimately contributes to the occurrence and development of cancer. BRAF mutations are widely present in various cancers, including malignant melanoma, thyroid cancer, colorectal cancer, non-small cell lung cancer, and hairy cell leukemia, among others. BRAF is an important target for the treatment of various solid tumors, and targeted combination therapies, represented by BRAF inhibitors, have become one of the main treatment modalities for a variety of BRAF-mutation-positive solid tumors. Dabrafenib plus trametinib, as the first tumor-agnostic therapy, has been approved by the US Food and Drug Administration for the treatment of adult and pediatric patients aged 6 years and older harboring a BRAF V600E mutation with unresectable or metastatic solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. This is also the first time a BRAF/MEK inhibitor combination has been approved for use in pediatric patients. As research into the diagnosis and treatment of BRAF mutations advances, standardizing the detection of BRAF mutations and the clinical application of BRAF inhibitors becomes increasingly important. Therefore, we have established a universal and systematic strategy for diagnosing and treating solid tumors with BRAF mutations. In this expert consensus, we (1) summarize the epidemiology and clinical characteristics of BRAF mutations in different solid tumors, (2) provide recommendations for the selection of genetic testing methods and platforms, and (3) establish a universal strategy for the diagnosis and treatment of patients with solid tumors harboring BRAF mutations.